GSK 250
  • Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
  • The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy in older adults, including those with underlying medical conditions, and in those with severe RSV disease
  • US launch is planned before the 2023/24 RSV season

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older adults to be approved anywhere in the world.

Tony Wood, Chief Scientific Officer, GSK, said: “Today marks a turning point in our effort to reduce the significant burden of RSV. Arexvy is the first approved RSV vaccine for older adults, expanding GSK’s industry-leading vaccine portfolio, which protects millions of people from infectious diseases each year. Our focus now is to ensure eligible older adults in the US can access the vaccine as quickly as possible and to progress regulatory review in other countries.”

Childrens 250

Registration is Open for the 2023 Children’s National Innovation Day & Showcase

Date: May 31, 2023 Time: 10:00 am - 7:00 pm Location: Children’s National Research and Innovation Campus (CNRIC), Washington, DC Registration Link: Click here to register

The organizers of the 2023 Children’s National Innovation Day & Showcase are thrilled to announce that registration is now open for this premier event highlighting innovation in pediatric healthcare. The event will take place on May 31, 2023, at the Children’s National Research and Innovation Campus (CNRIC) in Washington, DC.

Gaurav and Rich JPG

 

Join us on an informative episode of BioTalk with Rich Bendis as we delve into the fascinating realm of computer systems validation (CSV) and its significant impact on quality assurance in the life sciences industry. Our guest, Mr. Gaurav Walia, Senior Global Director of Business Development at PQE Group and Principal SME of Computer Systems Validation, Computer Software Assurance, and Data Integrity and Sr. Associate Partner, brings extensive expertise in CSV and compliance consulting services.

Discover the essential role of CSV in ensuring the integrity, reliability, and compliance of computerized systems used in pharmaceutical and medical device manufacturing. Mr. Walia, a recognized authority in the field, will provide insights into CSV's challenges and best practices, emphasizing the critical importance of regulatory adherence and data integrity.

Listen now via your favorite podcast platform

QuestHaystack
Haystack’s Highly Sensitive Minimal-Residual Disease Cancer-Detection Technology To Be Combined With Quest’s Oncology, Genomics And Pathology Expertise And Scale, Including Solid Tumor Sequencing, Convenient Specimen Collection And EHR Connectivity

SECAUCUS, N.J. and BALTIMORE, April 27, 2023 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic information services, and Haystack Oncology, an early-stage oncology company focused on minimal residual disease (MRD) testing to aid in the early, accurate detection of residual or recurring cancer and better inform therapy decisions, today announced a definitive agreement for Quest to acquire Haystack in an all-cash equity transaction.

MRD testing is a fast-growing category of liquid biopsy tests that identify circulating tumor DNA (ctDNA) in the bloodstream of patients following surgery and treatment for cancer. Founded in 2021, Haystack has developed a ctDNA-based technology specifically for MRD detection, based on 20 years of research and development by world-renowned luminaries from Johns Hopkins University, including Drs. Bert VogelsteinKen Kinzler and Nick Papadopoulos. In a prospective, multi-institution study published in the New England Journal of Medicine in June 2022, an earlier version of the Haystack technology demonstrated the ability to better identify patients with residual disease for adjuvant chemotherapy after surgery for stage II colon cancer, thereby reducing chemotherapy use in the overall patient population without compromising recurrence-free survival.

Kent2

Virginians have often sought experimental medical treatments outside the state — traveling to North Carolina, Boston or one of the Mayo Clinic’s locations. However, the Paul and Diane Manning Institute of Biotechnology at the University of Virginia aims to change that.

“We intend to tackle the biggest challenges in health care and to empower our researchers to make the life-changing breakthroughs that will transform care for people across Virginia and beyond,” says Dr. K. Craig Kent, CEO of UVA Health and executive vice president for health affairs at U.Va. “We’re on a cusp of a revolution in health care.”

Construction of the institute, which will be built in the 54-acre Fontaine Research Park adjacent to U.Va.’s Grounds, is set to be complete in 2026 or 2027. However, the university is forging ahead with hires, including about 100 scientists who will research potential treatments for diseases like diabetes and Alzheimer’s. Kent anticipates employing 1,000 to 1,400 people at the institute, which will include 30,000 to 40,000 square feet of lab space and a biomanufacturing facility.

DrugDisco

Analysis of international public-sector contributions to Food and Drug Administration (FDA)-approved drugs and vaccines allows for a more thorough examination of the global biomedical innovation ecosystem by institution of origin. Using new and existing methods, we have identified 364 FDA-approved drugs and vaccines approved from 1973 to 2016 discovered in whole or in part by Public Sector Research Institutions (PSRIs) worldwide. We identified product-specific intellectual property contributions to FDA-approved small molecule and biologic drugs and vaccines from the FDA Orange Book, our peer network, published studies, and three new sources: reports of medical product manufacturers’ payments to physicians and teaching hospitals under The Sunshine Act of 2010, a paper by Kneller and 64 royalty monetization transactions by academic institutions and/or their faculty that one of us (AS) maintains. We include a total of 293 drugs discovered either wholly by a US PSRI or jointly by a U.S. and a non-U.S. PSRI. 119 FDA-approved drugs and vaccines were discovered by PSRIs outside the U.S. Of these, 71 were solely discovered outside the US, while 48 also involved intellectual property contributions by US PSRIs. In the context of the global public sector landscape, the US dominates drug discovery, accounting for two-thirds of these drugs and many of the important, innovative vaccines introduced over the past 30 years. Contributions by Canada, UK, Germany, Belgium, Japan, and others each amount to 5.4% or less of the total.

Click here to read more from The Journal of Technology Transfer

RoosterBio

In this strategic partnership, RoosterBio becomes the first US-based service provider approved by NanoFCM to perform contract analytical services using the NanoAnalyzer platform.

FREDERICK, Md.April 26, 2023 /PRNewswire-PRWeb/ -- NanoFCM Co., Ltd today announced that RoosterBio, Inc. a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, development services, cell engineering, and advanced therapy bioprocess solutions, is approved to provide analytical services worldwide using NanoFCM's NanoAnalyzer.

In this strategic partnership, RoosterBio becomes the first US-based service provider approved by NanoFCM to perform contract analytical services using the NanoAnalyzer platform. RoosterBio has leveraged the NanoAnalyzer in its exosome / extracellular vesicle (EV) analytics workflows for over a year and offers this technology as a stand-alone service as well as integrated within broader exosome process development programs.

Seraxis log

GERMANTOWN, Md., April 25, 2023 (Newswire.com) - Seraxis Inc., a pre-clinical stage company with a best-in-class islet replacement therapy for insulin-dependent diabetes, today announced the presentation of results from an efficacy study of Synthetic Replacement Endocrine (SRE) pancreatic clusters. These data were presented by William Rust, PhD, Chief Executive Officer at Seraxis, as an oral podium presentation at the 4th International Pancreas and Islet Transplant Association (IPITA) / Harvard Stem Cell Institute (HSCI) / Juvenile Diabetes Research Fund (JDRF) Summit, held from April 24-25, 2023 in Cambridge, Massachusetts. The presentation included an introduction to Seraxis' proprietary GMP process for manufacturing SRE clusters for nonclinical and clinical use.

Emmes

Emmes collaborates with pharmaceutical companies as strategic partners, providing one-stop clinical trial services, reducing costs, and accelerating development.

SAN ANTONIO, TX. – April 25, 2023 – Frost & Sullivan researched the contract research organizations industry and, based on its analysis results, recognizes Emmes with the 2023 Global Competitive Strategy Leadership Award. Each year, Frost & Sullivan presents this award to the company that has leveraged competitive intelligence to successfully execute a strategy that results in stronger market share, competitive brand positioning, and customer satisfaction.

Emmes is a full-service, global Clinical Research Organization (CRO) committed to promoting public health and biopharmaceutical innovation. Its dedication to problem-solving, close collaboration with customers, and scientific excellence help its customers better understand complex research problems, generate higher-quality data, and enable better treatment options. The company has extensive therapeutic experience in common and rare diseases, which is backed up by specialized knowledge in biostatistics, biomedical data science and bioinformatics, and eClinical technologies.

ClinicalTrialsLogo

The value of life-saving drugs for patients suffering from serious diseases is priceless. But the current economic environment is stifling the biopharmaceutical pipeline of up-and-coming clinical trials. Dr. Harsha Rajasimha, Founder and CEO of Jeeva Informatics and the visionary behind Jeeva eClinical Cloud, appreciates the significant innovations that emerging biotech companies bring to the pursuit of early clinical development of novel therapeutics. He recommends an active front-loading strategy to maximize operational efficiency of clinical trials

Capra Logo

BioMADE Funding To Accelerate Capra Bioreactor Expansion and Technical Advancement, Aligning with New White House Bioeconomy Goals

MANASSAS, Va., April 24, 2023 (GLOBE NEWSWIRE) -- Capra Biosciences is scaling up their novel bioreactor technology to produce sustainable chemicals in Northern Virginia. This project was funded through a special BioMADE Project Call focused on advancing bioreactor design and development, thanks to support from Schmidt Futures. The expansion will jump start Virginia’s bioeconomy and place the state on the map for biochemical production.

The Manassas-based company uses a biofilm-forming microbe and its proprietary bioreactors to transform low-cost feedstocks, such as agricultural byproducts or food waste, into a variety of chemicals, including their first product, retinol.

“Our bioreactor platform is meant to handle small- or large-scale production of chemicals efficiently without a negative environmental impact,” said Dr. Andrew Magyar, Capra Biosciences’ chief technology officer. “We’ve already proved its potential on a smaller scale, and we’re excited to scale it for more chemicals and larger volumes. The new contract not only allows us to create a bigger facility, it also funds work with groundbreaking partners who will improve the efficiency and predictability of the bioreactors.”

JlabsEventMay2023

JLABS is taking the lead in exploring new and innovative approaches to vaccinations with their upcoming event, "Breaking Dependencies on Seasonal Vaccines to Address Infectious Diseases." This forward-looking program is scheduled to take place on Wednesday, May 17, 2023, at JLABS in Washington, DC, from 11:00 AM to 2:00 PM.

The event aims to examine the potential of technology to break the dependence on annual or seasonal vaccinations and provide more durable and reliable solutions for preventing infectious diseases such as coronaviruses, influenza, and rhinoviruses. Through innovation, there is an opportunity to enhance the impact and acceptance of vaccinations, achieve more consistent and impactful outcomes, and limit the spread of infectious diseases across large populations, regardless of risk level.

Johns Hopkins University Logo wine

Johns Hopkins University has launched a new, annual award to support promising business ventures developed by student entrepreneurs—and to encourage the creators of those startups to put down roots and grow in Baltimore.

The President's Venture Fellowship, by far the largest award for student entrepreneurship ever offered by the university, is open to any full-time Johns Hopkins student, undergraduate or graduate, who seeks to continue pursuing a business venture in Baltimore after graduation. Up to two winners will be selected annually to receive a $100,000 award, with the lead of each venture also receiving a $40,000 salary stipend.

 

CBRE 2023 US Life Sciences Outlook

After record years in 2020 and 2021, growth of the U.S. life sciences industry has returned to a more normal pace in 2023, although demand for lab/R&D space remains well above pre-pandemic levels. Life sciences employment reached a record high at the start of 2023, although the rate of growth slowed. The San Francisco Bay Area, Boston/Cambridge and Seattle were the fastest-growing markets last year.

Please see the reports below:

2023 U.S. Life Sciences Outlook

 

APECHEADER

 

 

 

 

 

 

BioHealth Innovation is proud to announce that Rich Bendis, Founder and CEO, will be participating in the upcoming International APEC Dialogue on Strengthening the Resilience of the Medical Product Supply Chain in the Asia Pacific.

Rich Bendis will be sharing his expertise in Panel Session Four: "The U.S. Capital Region’s Role in Enabling Global Medicines Supply Chain Resilience." This session offers a unique opportunity to gain insights into building a robust and resilient medical supply chain on a global scale.

This important event, cosponsored by the U.S. Food and Drug Administration (FDA) and the United States Pharmacopeia (USP), is aimed at accelerating efforts to strengthen medical product supply chains in the Asia Pacific region and beyond. Ensuring the resilience of these supply chains is a critical topic that impacts global health.

The program will take place on April 25 and 26, 2023, and will be a hybrid event, offering attendees the option to participate both in-person and virtually. The event will be held in conjunction with the USP Asia Pacific (APAC) Regional Chapter Meeting, which is scheduled for April 27, 2023.

Don't miss this opportunity to engage with experts and industry leaders in the field of medical supply chain resilience. Register now to attend in-person or virtually at the following link: https://cvent.me/2wVPXE